Correspondence |

Efficacy of Lenalidomide in Refractory Lupus Pernio

Virgil A. S. H. Dalm, MD, PhD; P. Martin van Hagen, MD, PhD
JAMA Dermatol. 2013;149(4):493-494. doi:10.1001/jamadermatol.2013.1313.
Text Size: A A A
Published online


Lupus pernio is a specific sarcoidosis skin lesion characterized by violaceous indurated plaques primarily affecting the central face. It is a hallmark of chronic disease, and treatment remains challenging because conventional therapies often fail.

Correspondence: Dr Dalm, Department of Immunology, Erasmus Medical Center, Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands (v.dalm@erasmusmc.nl).

Conflict of Interest Disclosures: None reported.

Funding/Support: The lenalidomide was provided for our patient by Celgene Corporation without charge; the drug is not registered in the Netherlands for the treatment of sarcoidosis and so its use in this context is not covered by health insurance.

Role of the Sponsor: Celgene Corporation had no role in the design and conduct of the study; in the collection, analysis and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Graphic Jump Location

Figure. Clinical images of our patient with lupus pernio. A, Frontal and coronal views prior to start of therapy with lenalidomide. B, Frontal and basal views 3 months after initiation of lenalidomide treatment, demonstrating an impressive improvement of skin lesions.




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics